We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

New Patented Technology Determines Who Should Receive COVID-19 Vaccine First by Tracing Coronavirus “Super Distributors”

By HospiMedica International staff writers
Posted on 23 Sep 2020
Illustration
Illustration
A new technology aims to determine which people should be first given the COVID-19 vaccine before the rest of the population to effectively stop the spread of the SARS-CoV-2 virus.

The technology developed by the Ehrlich Group (Ramat-Gan, Israel) was recently filed for a patent in the United Arab Emirates’ patent office, according to a report by the Jerusalem Post. The long-awaited COVID-19 vaccine is just months away from potentially curing the world from the SARS-CoV-2 virus, although it would take years to manufacture, distribute and vaccinate the entire world population.

Using data about the number of contacts and interactions by each individual, the new patented technology will establish priority guidelines for the vaccination of the population against COVID-19. The technology will trace "super-distributors” of the SARS-CoV-2 virus who will be given priority for administering the COVID-19 vaccine. The technology is based on the analysis of data collected from Israeli intelligence agencies or from various apps where users approve the use of their location data. By tracing and vaccinating super distributors of the SARS-CoV-2 virus, the chains of transmissions and infections within the community can be broken, making it possible to stop the spread of the SARS-CoV-2 virus even before the entire population is vaccinated, thus saving time and money, according to the Jerusalem Post report.

Related Links:
Ehrlich Group

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Head Rest
Medifa 61114_3

Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more